Panelists conclude that sNfL can be used as a biomarker to assess response to
treatment in future trials. In the clinic setting, it could become valuable in directing
therapy; for example, in cases in which the patient is absent clinical signs of aggressive
MS and it’s unclear if they will benefit from infused, injected, or oral disease-modifying
therapy.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS